Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1Genitourinary 1Gastrointestinal 1

Conditions

Lung Neoplasms 3Carcinoma, Non-Small-Cell Lung 3Neoplasm Metastasis 2Endometrial Neoplasms 2Stomach Neoplasms 1Small Cell Lung Carcinoma 1Salivary Gland Neoplasms 1Prostatic Neoplasms 1Pancreatic Neoplasms 1Myelodysplastic Syndromes 1Leukemia, Lymphocytic, Chronic, B-Cell 1Leukemia 1High Grade Serous Carcinoma 1Colorectal Neoplasms 1Colonic Neoplasms 1Cholangiocarcinoma 1Carcinosarcoma 1Carcinoma, Transitional Cell 1Carcinoma, Squamous Cell 1Carcinoma, Renal Cell 1Breast Neoplasms 1Adenocarcinoma 1

Interventions

pembrolizumab 22Nivolumab 14enfortumab vedotin 13Gemcitabine 11Specimen Handling 9Magnetic Resonance Spectroscopy 9Cisplatin 8Carboplatin 8sacituzumab govitecan 6Docetaxel 6avelumab 5atezolizumab 5Ipilimumab 5durvalumab 4Paclitaxel 4cabozantinib 3Taxes 3Mitomycin 3CTLA-4 Antigen 3tislelizumab 2relatlimab 2erdafitinib 2disitamab vedotin 2Radiosurgery 2Platinum 2Oxaliplatin 2Immunoglobulin G 2Fluorouracil 2Disulfides 2ALT-803 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Carcinoma, Transitional Cell × ceralasertib × 90 days × Clear all
NCT03682289 2026-04-23

Ceralasertib (AZD6738) Alone and in Combination With Olaparib or Durvalumab in Patients With Solid Tumors

University of California, San Francisco

Phase 2 Active not recruiting
83 enrolled
GastrointestinalGenitourinaryGynecologic

Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Neoplasm Metastasis, Pancreatic Neoplasms, Endometrial Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡